PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21739267-5 2012 Coadministration of fluvoxamine, a less potent CYP3A4 inhibitor, decreased the CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in IMs, indicating the same inhibitory effect on CYP enzymes, regardless of the CYP2D6 genotype. Fluvoxamine 20-31 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 110-116 21739267-5 2012 Coadministration of fluvoxamine, a less potent CYP3A4 inhibitor, decreased the CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in IMs, indicating the same inhibitory effect on CYP enzymes, regardless of the CYP2D6 genotype. Fluvoxamine 20-31 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 209-215 21739267-6 2012 Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration. Fluvoxamine 262-273 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 24-30 21739267-6 2012 Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration. Fluvoxamine 262-273 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 21739267-6 2012 Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration. Fluvoxamine 262-273 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 21739267-6 2012 Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration. Fluvoxamine 262-273 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 20547595-0 2011 CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Fluvoxamine 38-49 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 20547595-6 2011 We investigated the joint effect of smoking (an inducer of CYP1A2) and CYP2D6 genotype on interindividual variability in fluvoxamine steady-state concentration. Fluvoxamine 121-132 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 71-77 20547595-8 2011 While CYP2D6 genotype significantly influenced fluvoxamine concentration in all four dose groups (p < 0.05), the percentage variance explained (R2) by CYP2D6 decreased as the dose of fluvoxamine increased. Fluvoxamine 47-58 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 6-12 20547595-8 2011 While CYP2D6 genotype significantly influenced fluvoxamine concentration in all four dose groups (p < 0.05), the percentage variance explained (R2) by CYP2D6 decreased as the dose of fluvoxamine increased. Fluvoxamine 186-197 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 154-160 20547595-10 2011 Together, CYP2D6 genotype and smoking status explained 23% of the variance in fluvoxamine concentration but only at the low 50 mg/d dose group. Fluvoxamine 78-89 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 10-16 20547595-11 2011 These findings contribute to evidence-based and personalized choice of fluvoxamine dose using smoking status and CYP2D6 genetic variation. Fluvoxamine 71-82 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 113-119 20118554-0 2010 Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Fluvoxamine 65-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 33-52 21277363-4 2011 Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively. Fluvoxamine 0-19 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 211-217 20118554-7 2010 Among non-smoker patients, the C/D ratios of fluvoxamine in those with one and two mutated alleles of CYP2D6 were 1.6- and 1.4-fold higher, respectively, than those with no mutated alleles, though the differences among those three genotype groups were not significant. Fluvoxamine 45-56 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-108 14703714-4 2003 Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4. Fluvoxamine 59-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 18978520-0 2008 Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Fluvoxamine 65-76 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 29-35 18978520-3 2008 This study investigated the dose-dependent effect of CYP2D6-variant alleles on the steady-state fluvoxamine concentration. Fluvoxamine 96-107 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 53-59 18978520-9 2008 The present study suggests that the effect of the CYP2D6 genotype on fluvoxamine metabolism is greater at lower doses of fluvoxamine. Fluvoxamine 69-80 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 50-56 18978520-9 2008 The present study suggests that the effect of the CYP2D6 genotype on fluvoxamine metabolism is greater at lower doses of fluvoxamine. Fluvoxamine 121-132 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 50-56 18691982-11 2008 Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4. Fluvoxamine 59-70 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 16226034-8 2005 However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone. Fluvoxamine 25-36 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 155-161 16226034-8 2005 However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone. Fluvoxamine 140-151 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 155-161 19225771-0 2009 Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Fluvoxamine 60-71 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 22-28 19225771-1 2009 PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. Fluvoxamine 9-20 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-70 19225771-1 2009 PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. Fluvoxamine 22-25 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-70 18609433-2 2009 Fluvoxamine, a SSRI, is mainly metabolized by cytochrome P450 (CYP) 2D6 and 1A2. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-79 17516189-4 2007 The likely cause of the prolonged delirium was the interaction of promethazine and fluvoxamine through the inhibition of the CYP2D6 enzyme. Fluvoxamine 83-94 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 125-131 17484519-4 2007 The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol. Fluvoxamine 42-53 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 151-157 17484519-7 2007 These data suggest that CYP2D6 is the only enzyme predominantly responsible for the first-step oxidation of fluvoxamine to fluvoxamino alcohol, and alcohol dehydrogenase is involved in the second-step oxidation of fluvoxamino alcohol to the corresponding carbolic acid. Fluvoxamine 108-119 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 24-30 16205777-0 2006 Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Fluvoxamine 105-116 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 57-74 16205777-2 2006 CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism. Fluvoxamine 81-92 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-24 16205777-2 2006 CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism. Fluvoxamine 81-92 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 150-156 16205777-2 2006 CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism. Fluvoxamine 111-122 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-24 16205777-2 2006 CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism. Fluvoxamine 111-122 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 150-156 16205777-12 2006 5-HT2A receptor and CYP2D6 gene polymorphisms had a synergistic effect for the prediction of fluvoxamine-induced gastrointestinal side effects. Fluvoxamine 93-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 20-26 15199661-3 2004 Thus, fluoxetine, fluvoxamine and paroxetine are partially metabolised by CYP2D6, citalopram by CYP2C19 and sertraline by at least five different CYPs. Fluvoxamine 18-29 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 74-80 12883230-0 2003 Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Fluvoxamine 99-110 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 15-22 12610741-1 2003 OBJECTIVE: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms. Fluvoxamine 78-89 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 128-134 12618595-4 2003 The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (K(i), micromol/l) decreased in the order of fluoxetine (0.411) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9). Fluvoxamine 235-246 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 46-52 10917404-16 2000 An interaction with fluvoxamine may be of importance in poor metabolizers for CYP2D6. Fluvoxamine 20-31 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 78-84 11907488-1 2002 OBJECTIVES: Fluvoxamine is metabolized by the polymorphic cytochrome P450 (CYP) 2D6 and the smoking-inducible CYP1A2. Fluvoxamine 12-23 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 58-83 11876575-6 2002 Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 77-83 11791895-0 2001 The major fluvoxamine metabolite in urine is formed by CYP2D6. Fluvoxamine 10-21 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 55-61 11791895-1 2001 OBJECTIVE: Previous studies have shown that fluvoxamine is metabolized by CYP1A2 and CYP2D6, but there is no information on the impact the various CYP enzymes have on the different metabolic pathways of fluvoxamine biotransformation. Fluvoxamine 44-55 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 85-91 11791895-7 2001 RESULTS: Oral clearance of fluvoxamine was significantly higher in smokers, and significantly lower in CYP2D6 PMs than in non-smoking EMs. Fluvoxamine 27-38 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 103-109 11791895-12 2001 CONCLUSION: These results indicate that CYP2D6 catalyzes the major metabolic pathway of fluvoxamine, whereas CYP1A2 seems to catalyze other less important pathways. Fluvoxamine 88-99 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 40-46 11791895-13 2001 Both the CYP2D6 and the CYP1A2 pathways seem to be saturated in parallel with increasing fluvoxamine dosage. Fluvoxamine 89-100 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 9-15 11519155-5 2001 Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-109 11085201-3 2000 Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2. Fluvoxamine 25-36 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 60-85 10954064-1 2000 The cytochrome enzyme P450 2D6 (CYP2D6) is thought to play a role in the human metabolism of fluvoxamine. Fluvoxamine 93-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-30 10954064-1 2000 The cytochrome enzyme P450 2D6 (CYP2D6) is thought to play a role in the human metabolism of fluvoxamine. Fluvoxamine 93-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 10774624-6 2000 Fluvoxamine is metabolized to inactive metabolites by CYP1A2 and CYP2D6. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 65-71 9757149-0 1998 Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Fluvoxamine 10-21 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 59-65 10211917-0 1999 CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. Fluvoxamine 72-83 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 10471171-8 1999 Fluvoxamine is a potent inhibitor of CYP1A2, a moderate inhibitor of CYP3A and a mild inhibitor of CYP2D6. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 99-105 10051063-7 1999 Serotonin-specific reuptake inhibitor (SSRI) comedication (fluoxetine, two patients; citalopram, two patients; paroxetine, one patient; fluvoxamine, one patient) was significantly associated with 4.6-fold higher concentrations of parent compound, in keeping with an inhibitory action on CYP2D6 enzyme. Fluvoxamine 136-147 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 287-293 9817620-10 1998 CYP2D6 only makes up about 2-5% of the total P450 in the human liver, but anyway is the major enzyme catalyzing more than 30 clinically used drugs including all of the tricyclic antidepressants, several neuroleptics, opiates, betablockers, antiarrhythmics and among the SSRIs N-desmethylcitalopram, fluvoxamine, fluoxetine and paroxetine but not sertraline. Fluvoxamine 299-310 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 9757149-1 1998 OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam. Fluvoxamine 49-60 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 90-96 9757149-8 1998 For CYP1A2, CYP2D6, and CYP3A phenotypes, significant differences existed between baseline and fluvoxamine therapy. Fluvoxamine 95-106 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 12-18 9757149-13 1998 CONCLUSIONS: We concluded that fluvoxamine may cause significant inhibition of CYP1A2, CYP2D6, and CYP3A activity. Fluvoxamine 31-42 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 87-93 9617978-0 1998 Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. Fluvoxamine 105-116 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 58-64 9617978-3 1998 The antidepressants paroxetine and fluvoxamine are potent in vitro inhibitors of CYP2D6 and CYP1A2 isozymes, respectively. Fluvoxamine 35-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 81-87 9617978-6 1998 The aim of this study was to assess the determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition during paroxetine and fluvoxamine treatment. Fluvoxamine 149-160 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 98-104 9617978-16 1998 The extent of inhibition of CYP2D6 and CYP1A2 by paroxetine and fluvoxamine, respectively, displayed a positive correlation with baseline enzyme activity (p < 0.05). Fluvoxamine 64-75 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-34 9617978-18 1998 These data indicate that paroxetine and fluvoxamine treatment with minimum clinically effective doses significantly inhibit CYP2D6 and CYP1A2, respectively. Fluvoxamine 40-51 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 124-130 9617978-19 1998 The extent of inhibition of CYP2D6 by paroxetine and of CYP1A2 by fluvoxamine is dependent in part on the baseline enzyme activity. Fluvoxamine 66-77 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 28-34 10950475-3 1997 This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers. Fluvoxamine 177-180 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 40-46 9174682-0 1997 Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Fluvoxamine 21-32 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 54-60 9174682-5 1997 CONCLUSION: The results are consistent with a possible minor to moderate role of CYP2D6, but not CYP2C19, in fluvoxamine metabolism. Fluvoxamine 109-120 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 81-87 9184622-12 1997 Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 134-140 9174682-1 1997 OBJECTIVE: The purpose of this study was to investigate whether the disposition of fluvoxamine is associated with the CYP2D6 and CYP2C19 phenotype polymorphisms. Fluvoxamine 83-94 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 118-124 8968657-11 1996 CYP2D6 is inhibited by SSRIs, in order of decreasing potency paroxetine, norfluoxetine, fluoxetine, sertraline, citalopram and fluvoxamine. Fluvoxamine 127-138 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 8986013-5 1996 According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine. Fluvoxamine 258-269 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 117-123 8968657-19 1996 Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 63-69 8880055-0 1996 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Fluvoxamine 83-94 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 49-55 8838442-6 1996 The average apparent Ki values determined using CYP2D6-dependent dextromethorphan O-demethylation were: 33, 52 and 22 microM for rac-venlafaxine, R(+)-venlafaxine and S(-)-venlafaxine, respectively, vs 0.065 to 1.8 microM for paroxetine, fluoxetine, norfluoxetine, fluvoxamine and sertraline. Fluvoxamine 265-276 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 8880055-13 1996 CONCLUSION: This investigation confirms that paroxetine and fluoxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxetine are moderate inhibitors of CYP2C19 and that fluvoxamine is a potent inhibitor of CYP1A2 in humans in vivo. Fluvoxamine 180-191 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 96-102 8885123-1 1996 All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme. Fluvoxamine 52-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 105-124 8885123-1 1996 All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme. Fluvoxamine 52-63 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 126-132 8823236-0 1996 Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Fluvoxamine 15-26 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 70-76 8823236-2 1996 This study investigated the relationship between fluvoxamine disposition and the polymorphic CYP2D6 and the polycyclic aromatic hydrocarbon (as contained in cigarette smoke) inducible CYP1A2. Fluvoxamine 49-60 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 93-99 8823236-8 1996 CONCLUSION: The disposition of fluvoxamine in humans is associated with the polymorphic CYP2D6 activity, but CYP1A2 also seems to be involved. Fluvoxamine 31-42 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 88-94 8587855-3 1995 This review summarizes information to date regarding the inhibitory potency of fluoxetine, fluvoxamine, paroxetine, sertraline, nefazodone, and venlafaxine on five isoenzyme systems: CYP2D6, CYP3A3/4, CYP1A2, CYP2C9, and CYP2C19. Fluvoxamine 91-102 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 183-189 8880055-1 1996 OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine. Fluvoxamine 243-254 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 126-132 7622807-2 1995 From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme. Fluvoxamine 194-205 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 102-108 8685072-12 1995 This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450. Fluvoxamine 41-52 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 170-176 8846618-2 1995 The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine. Fluvoxamine 335-346 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 165-171 8846617-11 1995 CYP2D6, which is crucially involved in the metabolism of paroxetine and fluoxetine, appears to play a clinically insignificant role in the metabolism of fluvoxamine. Fluvoxamine 153-164 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 8846617-17 1995 Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 131-137 8567194-5 1995 As shown in another simple table, the author compared the hepatic enzymatic inhibitions of four selective serotonin reuptake inhibitors and pointed out the inhibition potentials of fluvoxamine at CYP1A2, fluoxetine and paroxetine at CYP2D6, and fluoxetine and fluvoxamine at CYP3A4 if these two SSRIs have higher serum concentrations. Fluvoxamine 181-192 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 233-239 34117140-13 2021 CONCLUSIONS: The effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety profiles of fluvoxamine was demonstrated in a group of 96 patients with depressive disorders comorbid with alcohol use disorder. Fluvoxamine 106-117 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 55-61 1389950-10 1992 Three other SSRIs, citalopram, desmethylcitalopram and fluvoxamine, were less potent inhibitors of CYP2D6, with apparent Ki-values of 19, 1.3 and 3.9 microM, respectively. Fluvoxamine 55-66 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 99-105 1389951-4 1992 Fluvoxamine (8.2 microM) and citalopram (5.1 microM) also inhibited CYP2D6 activity. Fluvoxamine 0-11 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 68-74 34605737-4 2021 For CYP2D6.39, the kcat values for fluvoxamine, fluoxetine, and milnacipran, but not for paroxetine and fluphenazine, gradually increased with increasing concentrations, indicating activation of the catalyzed reaction.3. Fluvoxamine 35-46 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 4-10 34117140-0 2021 Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. Fluvoxamine 80-91 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 38-44 34117140-1 2021 BACKGROUND: Previous studies have shown that cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of fluvoxamine, the activity of which is highly dependent, inter alia, on the polymorphism of the gene encoding it. Fluvoxamine 107-118 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 45-64 34117140-1 2021 BACKGROUND: Previous studies have shown that cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of fluvoxamine, the activity of which is highly dependent, inter alia, on the polymorphism of the gene encoding it. Fluvoxamine 107-118 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 66-72 34117140-2 2021 The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder. Fluvoxamine 130-141 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 88-94 34117140-2 2021 The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder. Fluvoxamine 130-141 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 161-167 34117140-2 2021 The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder. Fluvoxamine 130-141 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 194-200 34117140-3 2021 STUDY QUESTION: Efficacy and safety of fluvoxamine depend on the polymorphism of CYP2D6 gene in patients with major depressive disorder. Fluvoxamine 39-50 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 81-87 28361099-9 2017 Further, using a pharmacogenomics genotyping panel, we discovered that the patient had the CYP2D6 nonfunctioning variant genotype *4/*4 that results in very low metabolic activity on a number of psychotropic drugs, including fluvoxamine which he was prescribed. Fluvoxamine 225-236 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 91-97 33897064-3 2021 Previous research revealed that CYP2D6 is involved in the metabolism of fluvoxamine, the activity of which is highly dependent on the polymorphism of the gene encoding it. Fluvoxamine 72-83 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 32-38 29988737-0 2018 Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Fluvoxamine 70-81 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 11-17 29988737-2 2018 CYP2D6 is involved in the biotransformation of fluvoxamine. Fluvoxamine 47-58 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 0-6 29988737-4 2018 Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance. Fluvoxamine 139-150 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 80-86 29988737-4 2018 Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance. Fluvoxamine 277-288 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 80-86 29988737-9 2018 Conclusion: This study demonstrated the lower efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorders with GA genotype in CYP2D6 1846G>A polymorphic marker. Fluvoxamine 69-80 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 173-179